VICP on OTC

Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc. is an American pharmaceutical preparations company based in Cumming.¹ Its shares trade on OTC under the symbol VICP.¹

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

TickerVICP on OTC¹
IndustryPharmaceutical Preparations¹
HeadquartersCumming, Georgia¹
Incorporated inFL²
Business address1735 Buford Highway, Ste. 215-113, Cumming, Ga 30041²
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Company has yet to submit the business and development plan and is negotiating the extension of this requirement with MGH.⁴ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income⁵⁶⁷-$1.0M in 2023+37% since 2020

Net income⁸⁵⁶⁷-$1.2M in 2023−16% since 2019

Fiscal year	2019	2020	2021	2022	2023
Research and development	$99.0K⁸	$102.2K⁵	$17.7K⁶	$13.1K⁷	$15.3K⁷
Operating expenses			$336.9K⁶	$984.8K⁷	$1.0M⁷
Operating income		-$765.8K⁵	-$336.9K⁶	-$984.8K⁷	-$1.0M⁷
Income before tax			-$236.9K⁶	-$984.8K⁷	-$1.2M⁷
Net income	-$1.4M⁸	-$765.8K⁵	-$236.9K⁶	-$984.8K⁷	-$1.2M⁷
Earnings per share			-$0.01⁶	-$0.03⁷	-$0.03⁷
Earnings per share (diluted)				-$0.03⁷	-$0.03⁷
Shares (weighted, basic)			17.7M shares⁶	30.6M shares⁷	34.5M shares⁷
Shares (weighted, diluted)				30.6M shares⁷	34.5M shares⁷

Total assets⁸⁵⁶⁷$39.7K in 2023−94% since 2019

Shareholders’ equity⁸⁵⁶⁷-$1.9M in 2023+660% since 2018

Cash⁸⁵⁶⁷$9.4K in 2023−96% since 2019

Fiscal year	2018	2019	2020	2021	2022	2023	2024
Cash		$264.2K⁸	$1.3K⁵	$217.3K⁶	$14.1K⁷	$9.4K⁷
Current assets		$264.2K⁸	$1.3K⁵	$222.8K⁶	$72.0K⁷	$39.7K⁷
Intangible assets				$371.5K⁶
Total assets		$698.4K⁸	$404.1K⁵	$594.3K⁶	$72.0K⁷	$39.7K⁷
Accounts payable				$487.8K⁶	$272.3K⁷	$537.4K⁷
Short-term debt						$18.7K⁷
Current liabilities		$396.5K⁸	$853.2K⁵	$716.0K⁶	$1.0M⁷	$2.0M⁷
Retained earnings				-$14.1M⁶	-$15.1M⁷	-$16.3M⁷
Shareholders’ equity	-$253.7K⁸	$302.0K⁵	-$449.1K⁶	-$121.7K⁷	-$950.8K⁷	-$1.9M⁷
Shares outstanding		17.5M shares⁸	17.5M shares⁵	19.7M shares⁶	31.2M shares⁷	32.1M shares⁷	32.1M shares⁷

Cash from operations⁸⁵⁶⁷-$417.5K in 2023−57% since 2019

Fiscal year	2019	2020	2021	2022	2023
Cash from operations	-$970.3K⁸	-$262.9K⁵	-$444.0K⁶	-$238.2K⁷	-$417.5K⁷
Stock-based compensation			$4.3K⁶	$105.7K⁷	$20.7K⁷
Cash from investing			$100.0K⁶
Cash from financing			$560.0K⁶	$35.0K⁷	$412.8K⁷

Compare Vicapsys Life Sciences, Inc. with another company

Corporate structure

Vicapsys Life Sciences, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Vicapsys Life Sciences, Inc.

Wildcat Capital Management, LLC Filed SCHEDULE 13G on Vicapsys Life Sciences, Inc., latest Mar 21, 2025

Vicapsys Life Sciences, Inc. Cumming, Georgia
- ViCapsys, Inc. Subsidiary · Florida, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Vicapsys Life Sciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$9.4K⁷ Dec 31, 2023	$14.1K⁷ Dec 31, 2022	−33.2%

Intangibles and goodwill

Item	Latest	A year before	Change
Accumulated amortization	$0⁶ Dec 31, 2022	$121.0K⁶ Dec 31, 2021	−100.0%

Properties, in its own words

Our mailing address is 7778 Mcginnis Ferry Rd., Ste 270, Suwanee, GA 30024, which is a mailbox provided by an officer of the Company, we currently do not maintain a corporate office. Our telephone number is (972) 891-8033.

Item 2 of the 10-K filed Oct 21, 2024.⁴

Leadership

Who has led Vicapsys Life Sciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

Rodger Rees2009

2010201520202025

Chief financial officerRodger Rees Dec 14, 2009 to Dec 14, 2009¹¹

Board members and other officers (5)

Board memberFederico Pier Dec 9, 2009 to Dec 9, 2009¹²
Board memberMark Feldmesser Dec 9, 2009 to Dec 9, 2009¹³
Board memberMichael Yurkowski Dec 9, 2009 to Sep 8, 2010¹⁴
Board memberRodger Rees Dec 9, 2009 to Dec 9, 2009¹⁵
Board memberRyan Seddon Dec 9, 2009 to Dec 9, 2009¹⁶

Named in SEC Form D filings

People the company listed in its private-offering notices.

Chief Financial OfficerJeffrey Wright named Jul 13, 2023¹⁷
DirectorCharlie Farrahar named Jul 13, 2023¹⁷
DirectorColleen Delaney named Jul 13, 2023¹⁷
DirectorDorothy Jordan named Jul 13, 2023¹⁷
DirectorRichard Rosenblum named Jul 13, 2023¹⁷

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

ViCapsys, Inc. Florida³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

SSGI, INC.Jul 17, 2009 to Nov 7, 2016²

Timeline

Dec 27, 20238-K Entered a material agreement; New debt or obligation¹⁸
Jun 30, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares¹⁹
Jun 2, 20238-K Entered a material agreement²⁰
May 18, 20238-K Change of auditor²¹
May 17, 20238-K Change of auditor²²
Jan 12, 20238-K Executive or director change²³
Sep 28, 20228-K Executive or director change²⁴
Apr 12, 20228-K Executive or director change; Other events²⁵

Filings

35 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 8 major events, 1 insider forms, 1 large holders, 1 private raises, 11 other. The latest 20:

Mar 27, 202515-12G EDGAR
Mar 21, 2025SCHEDULE 13G EDGAR
Mar 21, 20253 EDGAR
Jan 10, 202510-Q EDGAR
Jan 10, 202510-Q EDGAR
Jan 10, 202510-Q EDGAR
Oct 21, 202410-K EDGAR
Jun 27, 2024SEC STAFF ACTION EDGAR
Dec 27, 20238-K EDGAR
Nov 14, 202310-Q EDGAR
Aug 14, 202310-Q EDGAR
Aug 9, 2023DEF 14C EDGAR
Jul 28, 2023PRE 14C EDGAR
Jul 13, 2023D EDGAR
Jun 30, 20238-K EDGAR
Jun 30, 2023S-1 EDGAR
Jun 2, 20238-K EDGAR
May 18, 20238-K/A EDGAR
May 17, 20238-K EDGAR
May 15, 202310-Q EDGAR

The 35 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Wildcat Capital Management, LLCSCHEDULE 13G, 1 filing Mar 21, 2025²⁶

Money raised

Private offerings the company reported to the SEC on Form D.

Jun 28, 2023Raised $330,000 in a private offering of securities Form D: 1 investor so far Form D

SEC filer profile

How Vicapsys Life Sciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARVicapsys Life Sciences, Inc.¹
CIK0001468639
Employer ID (EIN)91-1930691⁴
Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company⁴
Incorporated inFlorida⁴
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address1735 Buford Highway, Ste. 215-113, Cumming, GA 30041¹
Phone470-514-4013¹
Shares outstanding32,371,299 as of Dec 13, 2024⁹
Public float$4.7M as of Jun 30, 2024⁴
AuditorAssurance Dimensions, Coral Springs, Florida PCAOB ID 4048; no auditor attestation of internal control over financial reporting⁴
On EDGAR sinceJul 17, 2009¹
Filings92 in all: 10-Q (17), 8-K (12), 3 (9), UPLOAD (6), 10-K (5), D (5), NT 10-Q (4), 4 (3)¹
All 27 form types
CORRESP (3), DEF 14C (3), S-1/A (3), 10-12G/A (2), 8-K/A (2), NT 10-K (2), PRE 14C (2), S-1 (2), SC 13D (2), 10-12G (1), 15-12G (1), 15-15D (1), 3/A (1), 4/A (1), EFFECT (1), NT 10-K/A (1), SC 13G (1), SCHEDULE 13G (1), SEC STAFF ACTION (1)
Latest filingsAnnual report (10-K) Oct 21, 2024
Quarterly report (10-Q) Jan 10, 2025
Latest 8-K (8-K) Dec 27, 2023

Risk factors and legal proceedings

Legal proceedings

We know of no legal proceedings to which we are a party or to which any of our property is the subject which are pending, threatened or contemplated or any unsatisfied judgments against us.

The opening of Item 3, Legal Proceedings.⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARVicapsys Life Sciences, Inc. filings on SEC EDGAR
2
SEC EDGARVicapsys Life Sciences, Inc. filings on SEC EDGAR
3
SEC EDGARVicapsys Life Sciences, Inc. annual report, Exhibit 21 (subsidiaries)
4
SEC EDGARVicapsys Life Sciences, Inc. annual report, Item 1 (Business)
5
SEC EDGARVicapsys Life Sciences, Inc. 10-K for fiscal 2020
6
SEC EDGARVicapsys Life Sciences, Inc. 10-K for fiscal 2021
7
SEC EDGARVicapsys Life Sciences, Inc. 10-K for fiscal 2022
8
SEC EDGARVicapsys Life Sciences, Inc. 10-K for fiscal 2019
9
SEC EDGARVicapsys Life Sciences, Inc. 10-Q for fiscal 2024
10
SEC EDGARVicapsys Life Sciences, Inc. 10-Q for fiscal 2024
11
SEC EDGARRodger Rees, Chief financial officer
12
SEC EDGARFederico Pier, Board member
13
SEC EDGARMark Feldmesser, Board member
14
SEC EDGARMichael Yurkowski, Board member
15
SEC EDGARRodger Rees, Board member
16
SEC EDGARRyan Seddon, Board member
17
SEC EDGARVicapsys Life Sciences, Inc. Form D naming Jeffrey Wright
18
SEC EDGAREntered a material agreement; New debt or obligation
19
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
20
SEC EDGAREntered a material agreement
21
SEC EDGARChange of auditor
22
SEC EDGARChange of auditor
23
SEC EDGARExecutive or director change
24
SEC EDGARExecutive or director change
25
SEC EDGARExecutive or director change; Other events
26
SEC EDGARWildcat Capital Management, LLC SCHEDULE 13G on Vicapsys Life Sciences, Inc.